Skip to content
#artificial intelligence Review Open access

mRNA lipid nanoparticle vaccines: current status, challenges and future prospects

Sep 2026 · Molecular Biomedicine · Vol 7 · 0 citations · 253 references
Medicine

TL;DR

This review provides an integrated overview of recent advances in mRNA-LNP vaccines, covering mRNA molecular engineering, LNP composition and delivery mechanisms, immune responses, clinical progress, and current developmental challenges.

Abstract

mRNA vaccines have become a clinically validated vaccine platform, as demonstrated by the success of COVID-19 vaccines such as Comirnaty and Spikevax, owing to their rapid design, manufacturing scalability, and capacity to induce in situ antigen expression. A key factor underlying this success is the lipid nanoparticle (LNP) delivery system, which protects mRNA from degradation and promotes efficient cellular uptake and cytoplasmic delivery, thereby enabling the full potential of mRNA technology. The continued advancement of mRNA-LNP vaccines requires integrated optimization of mRNA design, LNP composition, and delivery strategies to achieve improved stability, efficient intracellular delivery, and balanced immune responses. Despite remarkable progress, challenges related to formulation stability, long-term storage stability, safety and reactogenicity concerns, and durability of immune protection continue to hinder the broader application of mRNA-LNP vaccine platforms. This review provides an integrated overview of recent advances in mRNA-LNP vaccines, covering mRNA molecular engineering, LNP composition and delivery mechanisms, immune responses, clinical progress, and current developmental challenges. Furthermore, emerging strategies, including thermostable formulations, next-generation LNPs with improved targeting capability, emerging RNA platforms, and artificial intelligence-assisted optimization of RNA sequences and lipid materials, are discussed. By summarizing current achievements and future opportunities, this review highlights key principles guiding the rational design of safer, more stable, and more precise mRNA-LNP vaccine platforms and provides insights into accelerating their clinical translation.

Read PDF

Similar papers

Review Open access Oct 2026

Bioengineering strategies for improving the immunogenicity of mRNA vaccines

Messenger RNA (mRNA) vaccines have reshaped modern vaccinology by enabling rapid antigen design, scalable manufacturing, and coordinated induction of humoral and cellular immunity. Their clinical success has established mRNA as a versatile platform for infectious diseases, cancer immunotherapy, and emerging therapeutic...

Hong Wang, Ran Zhuo, Jun-Jun Wu et al. · 0 citations
Aug 2026

Nitric oxide-assisted lipid nanoparticles amplify mRNA vaccine responses.

NO-assisted LNPs are established as a unique platform for potent mRNA delivery, which provides a new paradigm for overcoming endosomal barriers and improving the efficacy of mRNA vaccines.

Zheng-Wei Liu, Dinglingge Cao, Xu-Cheng Hou et al. · 0 citations
Review Aug 2026

Advances and Challenges in Nanodelivery Systems for RNA Vaccines.

The characteristics of three distinct types of RNA vaccines are focused on, as well as the applications of lipid nanoparticles, polymeric nanoparticles, virus-like particles, and other emerging nanocarriers in enhancing RNA stability, boosting immunogenicity, and enabling precise targeting.

Hang Li, Yubo Zhao, Jia-Jun Yang et al. · 0 citations
Review Open access Aug 2026

RNA vaccines in motion: A multidisciplinary exploration of design, delivery, and deployment

Overall, continued refinement of RNA sequence engineering and delivery systems positions these platforms as flexible tools for rapid-response vaccination and therapy, especially where fast antigen adaptation and scalable production are required.

Qamar Abuhassan, Ahmed Aldulaimi, O. Waleed et al. · 0 citations
Open access Aug 2026

LNP-CpG: deploy the self-adjuvant role of mRNA vaccines

With the rapid advancement of mRNA vaccines, lipid nanoparticles (LNPs) have emerged as pivotal carriers and adjuvants for non-mRNA vaccine modalities, driven by their superior nucleic acid delivery efficiency and intrinsic self-adjuvanting properties. In this study, we systematically evaluated various formulation stra...

Ning Luan, Han Cao, Xiaolong Zhang et al. · 0 citations
Sep 2026

Targeted Delivery of RNA-based Therapeutics by Lipid Nanoparticles.

Recent advancements in ionizable lipid chemistry, microfluidic formulation, and targeted delivery techniques are broadening the therapeutic potential of LNPs, reinforcing their significance as essential carriers in the forthcoming era of precision RNA medicine.

Shayeri Chatterjee Ganguly, Priya Manna, Satadeep Bandyapadhyay et al. · 0 citations

Related blog posts

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.